Morinet F, Courouce A M, Galibert F, Perol Y
Hôpital Saint-Louis, Université Paris VII, Service de Bactériologie-Virologie, France.
Behring Inst Mitt. 1990 Aug(85):28-34.
A new anti-B19 IgM ELISA was developed using the antibody-capture principle. Biotinylated fusion protein was used as antigen. The specificity of the test was analysed using sera IgM positive to rubella, hepatitis B core antigen, cytomegalovirus and Epstein Barr virus as well with sera positive for rheumatoid factors, antinuclear antibodies and with sera from normal blood donors. The specificity of the test was 96.18%. One hundred serum samples were tested by the new ELISA and the standard MACRIA tests for the presence of B19 IgM. Eighty-eight sera gave the same results with both tests. Fifty-three were negative and 35 were positive. Six sera were ELISA negative MACRIA positive and six MACRIA negative ELISA positive. In a clinical study with 725 sera from suspected B19 infections, 161 (22%) were recorded as positive by the ELISA test. The positive sera were from patients suffering from arthritis (35%), rash (35%), acute or chronic erythroblastopenia (21%), pancytopenia (5%), vascular purpura (2%) and lymphadenopathy (2%).
利用抗体捕获原理研发了一种新型抗B19 IgM酶联免疫吸附测定法。生物素化融合蛋白用作抗原。使用风疹、乙肝核心抗原、巨细胞病毒和EB病毒IgM阳性血清以及类风湿因子、抗核抗体阳性血清和正常献血者血清分析该检测方法的特异性。该检测方法的特异性为96.18%。通过新型酶联免疫吸附测定法和标准微量血细胞凝集抑制反应试验检测了100份血清样本中B19 IgM的存在情况。88份血清在两种检测中结果相同。53份为阴性，35份为阳性。6份血清酶联免疫吸附测定法阴性但微量血细胞凝集抑制反应试验阳性，6份血清微量血细胞凝集抑制反应试验阴性但酶联免疫吸附测定法阳性。在一项对725份疑似B19感染血清的临床研究中，酶联免疫吸附测定法记录为阳性的有161份（22%）。阳性血清来自患有关节炎（35%）、皮疹（35%）、急性或慢性成红细胞减少症（21%）、全血细胞减少症（5%）、血管性紫癜（2%）和淋巴结病（2%）的患者。
